These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1509 related articles for article (PubMed ID: 27882879)
1. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879 [TBL] [Abstract][Full Text] [Related]
2. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. Marín-Cabañas I; Berbegal-de Gracia L; de León-Marrero F; Hispán P; Silvestre JF Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634 [TBL] [Abstract][Full Text] [Related]
3. Current and future therapies for treating chronic spontaneous urticaria. Maurer M; Vena GA; Cassano N; Zuberbier T Expert Opin Pharmacother; 2016 Jun; 17(8):1131-9. PubMed ID: 26918673 [TBL] [Abstract][Full Text] [Related]
4. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study. Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658 [TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of chronic spontaneous urticaria. Makris M; Maurer M; Zuberbier T Expert Opin Pharmacother; 2013 Dec; 14(18):2511-9. PubMed ID: 24195758 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population. Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043 [TBL] [Abstract][Full Text] [Related]
7. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957 [TBL] [Abstract][Full Text] [Related]
8. Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics. Hon KL; Li JTS; Leung AKC; Lee VWY Expert Opin Pharmacother; 2021 Mar; 22(4):497-509. PubMed ID: 32990110 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Giménez-Arnau AM Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304 [TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study. Buono EV; Giannì G; Scavone S; Caffarelli C Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792886 [No Abstract] [Full Text] [Related]
11. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria. Sánchez J; Zakzuk J; Cardona R J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab for the treatment of chronic urticaria. Zuberbier T; Maurer M Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680 [TBL] [Abstract][Full Text] [Related]
13. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A; Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719 [TBL] [Abstract][Full Text] [Related]
14. Chronic Urticaria: Following Practice Guidelines. Westby EP; Lynde C; Sussman G Skin Therapy Lett; 2018 May; 23(3):1-4. PubMed ID: 29772036 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. Ghazanfar MN; Holm JG; Thomsen SF J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. Metz M; Ohanyan T; Church MK; Maurer M J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603 [TBL] [Abstract][Full Text] [Related]
17. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500 [TBL] [Abstract][Full Text] [Related]
18. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720 [TBL] [Abstract][Full Text] [Related]
19. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128 [TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium. Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]